A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
- Status
- COMPLETED
- Phase
- PHASE3
Clinical Trials Related to Lenvatinib
Related studies linked through entity extraction aliases.
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
A Study of Overall Survival in Participants With Unresectable Hepatocellular Carcinoma
- Status
- COMPLETED
- Phase
- N/A
Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)
- Status
- COMPLETED
- Phase
- PHASE3
Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Phase II of Lenvatinib Plus Toripalimab for Advanced HCC
- Status
- WITHDRAWN
- Phase
- PHASE2
TACE With Lenvatinib Versus Lenvatinib Alone in in First-line Treatment of Advanced HCC
- Status
- UNKNOWN
- Phase
- PHASE3
Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC
- Status
- RECRUITING
- Phase
- PHASE2
Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)
- Status
- COMPLETED
- Phase
- PHASE3
Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001)
- Status
- COMPLETED
- Phase
- PHASE3
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
- Status
- TERMINATED
- Phase
- PHASE1
Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage Hepatocellular Carcinoma
- Status
- COMPLETED
- Phase
- PHASE2
Lenvatinib Combined With TACE to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma
- Status
- UNKNOWN
- Phase
- NA
Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007)
- Status
- COMPLETED
- Phase
- PHASE3
Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)
- Status
- COMPLETED
- Phase
- PHASE3
Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)
- Status
- COMPLETED
- Phase
- PHASE3
HAIC Plus Lenvatinib and PD-1 Antibody Versus HAIC Plus Lenvatinib for Advanced HCC
- Status
- WITHDRAWN
- Phase
- PHASE2
Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma
- Status
- WITHDRAWN
- Phase
- PHASE2
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)
- Status
- COMPLETED
- Phase
- PHASE2
Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven Criteria
- Status
- WITHDRAWN
- Phase
- PHASE3